Trials / Completed
CompletedNCT00869895
A Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors
A Phase I Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of E7050 given orally in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7050 | Oral dosing starting at 100 mg once daily. After the MTD of once daily dosing has been determined, subsequent cohorts will be treated with a divided dosing schedule either twice or three times daily. The starting dose for this schedule will be an appropriate level below the MTD for once daily dosing. |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2012-08-01
- First posted
- 2009-03-26
- Last updated
- 2016-01-29
Locations
2 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00869895. Inclusion in this directory is not an endorsement.